Estimating the economic costs of antimicrobial resistance
Model and Results
ResearchPublished Dec 10, 2014
Model and Results
ResearchPublished Dec 10, 2014
The independent Review on AMR led by the economist Jim O'Neill commissioned RAND Europe to conduct a study estimating the global costs of antimicrobial resistance until 2050 in the absence of any progress in tackling the challenge. We developed a general equilibrium model, which calculated the extent of losses to the world economy caused by decreases in the supply of labour resulting from resistant hospital acquired infections and selected major infectious diseases (HIV, TB, malaria). Our approach incorporated a set of seven scenarios with varying rates of future resistance, time of onset of increases in resistance, and availability of effective second-line therapy.
The research described in this report was prepared for the Independent Review on Antimicrobial Resistance and conducted by RAND Europe.
This publication is part of the RAND research report series. Research reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND research reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.